Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PULSE BIOSCIENCES, INC.

(PLSE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pulse Biosciences : Grants Equity Incentive Awards To New Employees

09/15/2020 | 04:15pm EDT

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 77,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on September 15, 2020.

The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual’s entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

The options have an exercise price of $11.67 per share, which is equal to the closing price of Pulse Biosciences common stock on September 15, 2020. The 77,250 shares underlying the option grants will vest and become exercisable as to 25% of the shares annually beginning on the first anniversary of the recipient’s start date, subject to the recipient’s continued employment with Pulse Biosciences on these vesting dates. The options are subject to the terms and conditions of the 2017 Inducement Equity Incentive Plan and the award agreements entered into with each recipient.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients. If cleared, the CellFX® System will be the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Subject to regulatory approval, the initial commercial use of the CellFX System is expected to address a broad range of dermatologic conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes. Designed as a multi-application platform, the CellFX System is intended to offer customer value with a utilization-based revenue model across an expanding spectrum of clinical applications. To learn more please visit www.pulsebiosciences.com.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.


ę Business Wire 2020
All news about PULSE BIOSCIENCES, INC.
06/10PULSE BIOSCIENCESá : AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN ..
PU
06/09PULSE BIOSCIENCESá : Wins Canada Regulatory Ok for CellFX System
MT
06/09PULSE BIOSCIENCESá : Announces Health Canada Approval for CellFX« System (Form 8..
PU
06/09PULSE BIOSCIENCES, INC.á : Other Events, Financial Statements and Exhibits (form..
AQ
06/09PULSE BIOSCIENCESá : Announces Health Canada Approval for CellFX« System
BU
05/24PULSE BIOSCIENCESá : to Participate in the Jefferies Healthcare Conference
BU
05/20PULSE BIOSCIENCES, INC.á : Submission of Matters to a Vote of Security Holders (..
AQ
05/13PULSE BIOSCIENCESá : reg; Presents Clinical Study Results of Nano-Pulse Stimulat..
BU
05/12PULSE BIOSCIENCESá : Reports First Quarter 2021 Financial Results (Form 8-K)
PU
05/10PULSE BIOSCIENCESá : Management's Discussion and Analysis of Financial Condition..
AQ
More news
Financials (USD)
Sales 2021 1,20 M - -
Net income 2021 -83,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,59x
Yield 2021 -
Capitalization 462 M 462 M -
Capi. / Sales 2021 385x
Capi. / Sales 2022 10,5x
Nbr of Employees 95
Free-Float 47,8%
Chart PULSE BIOSCIENCES, INC.
Duration : Period :
Pulse Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PULSE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 42,93 $
Last Close Price 17,46 $
Spread / Highest target 163%
Spread / Average Target 146%
Spread / Lowest Target 129%
EPS Revisions
Managers and Directors
NameTitle
Darrin R. Uecker President, Chief Executive Officer & Director
Sandra A. Gardiner CFO, Secretary, Treasurer & Executive VP-Finance
Robert William Duggan Chairman
Richard Nuccitelli Chief Science Officer
David Danitz Vice President-Engineering
Sector and Competitors
1st jan.Capitalization (M$)
PULSE BIOSCIENCES, INC.-26.82%462
THERMO FISHER SCIENTIFIC-0.14%182 817
DANAHER CORPORATION11.20%176 194
INTUITIVE SURGICAL, INC.5.64%102 341
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.10.33%89 297
ILLUMINA, INC.22.48%66 163